Cogent Biosciences (COGT) Accumulated Expenses (2017 - 2026)
Cogent Biosciences (COGT) posted quarterly Accumulated Expenses of $6.2 million for Q1 2026, up 69.18% year-over-year from $3.7 million in Q1 2025, and down 60.58% quarter-over-quarter from $15.7 million in Q4 2025.
Cogent Biosciences (COGT) Accumulated Expenses (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Accumulated Expenses for 10 consecutive years, with $6.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses rose 69.18% year-over-year to $6.2 million; the TTM figure through Mar 2026 stood at $6.2 million (up 69.18% YoY), while the FY2025 annual figure was $15.7 million, down 62.64% from the prior year.
- Accumulated Expenses fell to $6.2 million in Q1 2026 per COGT's latest filing, from $15.7 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $42.1 million in Q4 2024 and bottomed at $1.5 million in Q1 2022.
- Historically, Accumulated Expenses has averaged $10.5 million across 5 years, with a median of $7.7 million in 2024.
- Annual changes were most pronounced in 2023 — Accumulated Expenses surged 1000.48% — and 2024, when it sank 84.81%.
- Cogent Biosciences' Accumulated Expenses stood at $17.9 million in 2022, then slumped by 44.79% to $9.9 million in 2023, then jumped by 326.7% to $42.1 million in 2024, then tumbled by 62.64% to $15.7 million in 2025, then sank by 60.58% to $6.2 million in 2026.
- Business Quant data shows COGT's Accumulated Expenses at $6.2 million in Q1 2026, $15.7 million in Q4 2025, and $10.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.32 Mn |
| Mar 31, 2026 | 6.20 Mn |
| Dec 31, 2025 | 15.74 Mn |
| Sep 30, 2025 | 10.50 Mn |
| Jun 30, 2025 | 8.13 Mn |
| Mar 31, 2025 | 3.67 Mn |
| Dec 31, 2024 | 42.13 Mn |
| Sep 30, 2024 | 7.73 Mn |
| Jun 30, 2024 | 5.68 Mn |
| Mar 31, 2024 | 2.43 Mn |
| Dec 31, 2023 | 9.87 Mn |
| Sep 30, 2023 | 5.87 Mn |
| Jun 30, 2023 | 17.42 Mn |
| Mar 31, 2023 | 16.00 Mn |
| Dec 31, 2022 | 17.88 Mn |
| Sep 30, 2022 | 4.07 Mn |
| Jun 30, 2022 | 3.16 Mn |
| Mar 31, 2022 | 1.45 Mn |
| Dec 31, 2021 | 3.39 Mn |
| Sep 30, 2021 | 2.05 Mn |